About Lyell Immunopharma
Lyell Immunopharma is a publicly listed company based in San Francisco (United States) founded in 2018 by Rick Klausner. CAR-T and TIL immunotherapies for solid tumors are developed. Lyell Immunopharma has raised $493 million across 3 funding rounds from investors including Mubadala, Arch Venture Partners and GSK. The company has 233 employees. Lyell Immunopharma has completed 1 acquisition, including ImmPACT-Bio. Lyell Immunopharma was last valued at $4.37 billion in June 2021. Its website lyell.com draws about 14 thousand monthly visits. Lyell Immunopharma offers products and services including LYL314 and CAR T-cell Therapies. Its focus areas include Life Sciences, Immunotherapy, Adoptive Cell Therapy and T-Cell. Its legal entity is Lyell Immunopharma, Inc. Its competitors include Poseida Therapeutics, Juno Therapeutics and TScan Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2018 and based in San Francisco, United States, the biotechnology firm focuses on oncology. CAR-T therapies are advanced for treating ROR1-positive non-small cell lung cancer and triple-negative breast cancer through the lead program LYL797. An autologous TIL therapy, LYL845, is pursued for multiple solid tumors. Operations center on clinical development of these immunotherapies to address unmet needs in cancer care.
- Annual Revenue$36 K (USD)-40.98as on Dec 31, 2025
- Net Profit-$274.45 M (USD)19.98as on Dec 31, 2025
- EBITDA-$192.24 M (USD)5.89as on Dec 31, 2025
- Total Equity Funding$493M (USD)
in 3 rounds
- Latest Funding Round$100M (USD), Post-IPO
Jul 2025
- InvestorsMubadala
& 6 more
- Employee Count233
- Investments & Acquisitions
Products & Services of Lyell Immunopharma
Lyell Immunopharma offers a comprehensive portfolio of products and services, including LYL314 and CAR T-cell Therapies.
Targets relapsed large B-cell lymphoma through advanced cell therapies
Develops treatments for solid tumors and hematologic malignancies
Funding Insights of Lyell Immunopharma
Lyell Immunopharma has successfully raised a total of $493M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $100 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $493M
- Total Rounds 3
- Last Round Post-IPO — $100M
- Investors Count 7
All 3 funding rounds of Lyell Immunopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2025 | $100M | Post-IPO | – | – | – |
| Mar 2020 | $493M | Series C | – | GSK | – |
| Jun 2018 | Seed | – | Sahsen Ventures | – |
| Date | Valuation | Stage |
|---|
Full valuation and stage history of Lyell Immunopharma
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $4.37B (Jun 2021). 7 investors in total: 7 institutional.
Investors in Lyell Immunopharma
Lyell Immunopharma has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Mubadala, Arch Venture Partners and GSK.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in multiple sectors are made by Sahsen Ventures. | sahsen.com | Seattle, United States | ||
Venture capital firm investing in technology, life sciences, and related sectors. | 8vc.com | |||
Multi-stage investment firm invests in healthcare and life sciences companies | foresitecapital.com | New York, United States | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Venture capital firm focused on multiple sectors | shakeandbakeproductions.com | Los Angeles, United States | ||
Developer of pharmaceuticals and vaccines for various therapeutic areas | 1715 | gsk.com | Brentford, United Kingdom | |
Sovereign wealth fund of United Arab Emirates | 2002 | mubadala.com | Abu Dhabi, United Arab Emirates |
Investor details for Lyell Immunopharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Lyell Immunopharma
69 people are tracked at Lyell Immunopharma (37 in leadership, 8 in board & advisors, 24 in team); the tracked headcount is 233.
| Name | Role | Group |
|---|---|---|
Rick Klausner | Co-Founder | Leadership |
Elizabeth Saccone M.b.a., Asq (Beth) | Head Of Business Operations & Program Management, Product Lead | Leadership |
Jeff Eskew | VP Clinical Sciences | Leadership |
Ryan M Smith | Director Of Procurement | Leadership |
James Cregg | Director Of Automation At Lyell Immunopharma | Leadership |
Gary Lee | Chief Scientific Officer | Leadership |
Marcia Friedman | Medical Director | Leadership |
Ann Tomlin | Senior Vice President, Head Of Human Resources | Leadership |
Ellen Rose | Senior Vice President, Communications & Investor Relations | Leadership |
Dylan Lewis Cfa, Cpa, Ca | Associate Director, SEC Reporting & Technical Accounting | Leadership |
Ajath S. | Vice President Information Technology & Information Sciences | Leadership |
Lynn Seely | President & Chief Executive Officer | Leadership |
Stephen Hill | Chief Operating Officer | Leadership |
Tina Albertson | Chief Medical Officer & Head of Development | Leadership |
Neeraj S. | Principal Scientist/associate Director | Leadership |
Shobha Potluri | Vice President Of Bioinformatics | Leadership |
Peter Tran | Director, Corporate Finance & Business Development | Leadership |
Martin E Wohlfahrt | Associate Director | Leadership |
Kristen Benzel | Director Of Accounting | Leadership |
Rachel Lynn | Senior Director | Leadership |
49 more people are available in the full profile.
Complete people profiles for Lyell Immunopharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Lyell Immunopharma
Lyell Immunopharma is a publicly listed company on the NASDAQ with ticker symbol LYEL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Jun 2021
- Listed onNASDAQ: LYEL
- Listed entityLyell Immunopharma, Inc.
- Exchange sectorHealth technology
- ISINUS55083R2031
- Share price$7.51 (-9.19% on the day) · 2026-10-13
- Market capitalisation$184.0M
- EPS (diluted, trailing year)$-11.77
- Volume (last session)187,174
Financials of Lyell Immunopharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $36,000 | -$274.4M | -$192.2M |
| 2024 | $61,000 | -$343.0M | -$204.3M |
| 2023 | $130,000 | -$234.6M | -$230.5M |
| 2022 | $84.7M | -$183.1M | -$175.3M |
| 2021 | $10.7M | -$250.2M | -$202.6M |
Detailed financial statements for Lyell Immunopharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lyell Immunopharma
Lyell Immunopharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ImmPACT-Bio.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Biotechnology research and development are conducted in Israel. | immpact-bio.com | Ness Ziona, Israel | 2017 | Oct 2024 | •••• |
Complete acquisition details for Lyell Immunopharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Lyell Immunopharma
6 dated milestones of Lyell Immunopharma across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Lyell Immunopharma is founded.
- Funding First funding round.
- Milestone Reaches Unicorn status.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires ImmPACT-Bio.
- Funding Latest funding round, Post-IPO, of $100.0M.
Competitors of Lyell Immunopharma
Lyell Immunopharma has 3 listed competitors in our database, 3 of them funded. They include Poseida Therapeutics, Juno Therapeutics and TScan Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| junotherapeutics.com | 2013 | Seattle, United States | $316.67M | 520 | CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | |
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. |
Detailed competitors of Lyell Immunopharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Lyell Immunopharma
The website of Lyell Immunopharma (lyell.com) receives about 14.3K visits a month and ranks #3,232,661 among all websites worldwide, #4,246 in Biotechnology and Pharmaceuticals.
- Monthly visits14.3K
▲ 111.8% vs previous month
- Unique visitors3K
per month
- Global rank#3,232,661
among all websites
- Category rank#4,246
Health · Biotechnology and Pharmaceuticals
- Bounce rate53%
- Pages per visit1.5
- Average visit24 sec
- DevicesDesktop 54% · Mobile 46%
Websites whose visitors overlap most with Lyell Immunopharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| agcbio.com | 100% | #910,858 | View details | ||
| obsidiantx.com | 98% | 8K | #3,203,206 | View details | |
| athira.com | 88% | 4.9K | #4,394,066 | View details | |
| lundbeck.com | 80% | 137.6K | #280,857 | View details | |
| biopharmadive.com | 80% | 680.7K | #208,628 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Lyell Immunopharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
3 companies that operate in the same segment as Lyell Immunopharma (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | |||
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | 253 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lyell Immunopharma
Complete news archive for Lyell Immunopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lyell Immunopharma
Lyell Immunopharma was founded in 2018.
Lyell Immunopharma is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Lyell Immunopharma is a funded company, having raised a total of $493M across 3 funding rounds to date.
Lyell Immunopharma has 233 employees.
Annual revenue of Lyell Immunopharma is $36K as on Dec 31, 2025.
Founded in 2018 and based in San Francisco, United States, the biotechnology firm focuses on oncology. CAR-T therapies are advanced for treating ROR1-positive non-small cell lung cancer and triple-negative breast cancer through the lead program LYL797. An autologous TIL therapy, LYL845, is pursued for multiple solid tumors. Operations center on clinical development of these immunotherapies to address unmet needs in cancer care.
Lyell Immunopharma's top competitors include Juno Therapeutics, Poseida Therapeutics and TScan Therapeutics.
Lyell Immunopharma offers LYL314 and CAR T-cell Therapies.
Yes, Lyell Immunopharma is publicly traded on NASDAQ under the ticker symbol LYEL.
Lyell Immunopharma has made 1 acquisition, including ImmPACT-Bio.
Lyell Immunopharma has 7 investors. Key investors include Mubadala, Arch Venture Partners, GSK, Sahsen Ventures, and 8VC.
The valuation of Lyell Immunopharma is $4.37B as of Jun 2021.